# ML-016 in Advanced Cancer With Lung and/or Liver Involvement

Source: https://onco.cc/trials/nct07723482/  
OnCo record `nct07723482` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by BrYet US, Inc., now recruiting.

## Summary

ML-016 in Advanced Cancer With Lung and/or Liver Involvement is a phase 1/2, interventional study registered as NCT07723482 by BrYet US, Inc., with a registry enrolment figure of 108 participants, started 2026-08 and due to reach its primary completion in 2027-08. Interventions recorded: ML-016. Conditions listed: Advanced Solid Tumor With Lung and/or Liver Involvement. Primary outcome: Incidence of dose-limiting toxicities (DLTs) during the DLT assessment period; Frequency and severity of adverse events (AEs) and serious AEs (SAEs); Maximum tolerated dose (MTD) and doses recommended for expansion. Lung eligibility wording from the registry: "Evidence of tumor in the lung and/or liver based on imaging studies". Sites: Australia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-19
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07723482
- Phase: 1/2
- Setting: Phase 1/2 Study of ML-016 in Participants With Advanced Cancer With Lung and/or Liver Involvement
- Sponsor: BrYet US, Inc.
- Enrolled: 108

## Notes

- Registry status on 19 October 2026: Recruiting (registry record last updated 5 October 2026; primary completion expected October 2027).

## Sources

- ClinicalTrials.gov NCT07723482: https://clinicaltrials.gov/study/NCT07723482

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)
- companies: [BrYet](https://onco.cc/companies/bryet/)

---
JSON: https://onco.cc/api/v1/entities/nct07723482.json